Bleeding risk with the new oral anticoagulant drugs (NOACs) is increased when they are used with some other medications, including amiodarone, often co-prescribed with these agents, a new study warns.

A common scenario: a patient presents with new-onset atrial fibrillation (AF) and multiple risk factors for stroke. Everyone agrees to use anticoagulant therapy to reduce the risk of stroke. The ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

Patients with nonvalvular atrial fibrillation treated with non-vitamin K oral anticoagulants (NOACs) have a heightened risk of major bleeding when also treated with other medications, including ...

Stroke patients treated with intravenous alteplase (Activase) did not have more intracranial hemorrhages if they had recently taken non-vitamin K antagonist oral anticoagulants (NOACs), according to ...

In my practice, I’ve used all the NOAC (novel anticoagulant) therapies available for stroke prevention in my nonvalvular atrial fibrillation patients. I have used dabigatran in my nonvalvular atrial ...

HOUSTON, TX—There’s no such thing as a good intracranial hemorrhage (ICH), but a new analysis hints that patients who have one might be better off if they’re taking a non-vitamin K antagonist oral ...

Switching vitamin K antagonist (VKA) treatment to a non-vitamin K antagonist oral anticoagulant (NOAC) in frail elderly patients with atrial fibrillation is associated with more bleeding complications ...

Despite guideline recommendations, evidence for the use of non–vitamin K antagonist oral anticoagulant (NOAC) monotherapy in patients with atrial fibrillation after implantation of a drug-eluting ...

NEW YORK--(BUSINESS WIRE)-- In response to the nation’s opioid epidemic, the National Opioid Action Coalition (NOAC), formed by Fors Marsh Group (FMG), iHeartMedia, and WPP, today announced the launch ...

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.